The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Genasense oblimersen | Genta Development Ltd. c/o Ross Craig | Melanoma | 🇪🇺 EU 2007-07-19 | Order → |
| Gevalka ensartinib | SFL Pharmaceuticals Deutschland GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2026-09-17 | Order → |
| Graspa Orphan | ERYTECH Pharma S.A. | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU | Order → |
| HemAryo eptacog alfa (activated) | UGA Biopharma | Hemophilia A; Hemophilia B; Factor VII Deficiency | 🇪🇺 EU | Order → |
| Heparesc human heterologous liver cells Orphan | Cytonet GmbH KG | Urea Cycle Disorders, Inborn | 🇪🇺 EU 2015-10-22 | Order → |
| Heplisav | Dynavax International B.V. | Hepatitis B | 🇪🇺 EU | Order → |
| Hervelous trastuzumab Biosimilar | Prestige Biopharma Belgium | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU | Order → |
| Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech human IgG1 monoclonal antibody specific for human interleukin-1 alpha | XBiotech Germany GmbH | Colorectal Neoplasms | 🇪🇺 EU 2017-09-14 | Order → |
| Hyalograft C autograft | Anika Therapeutics S.r.l. | 🇪🇺 EU | Order → | |
| Hydrocortisone Aguettant hydrocortisone | Laboratoire Aguettant | Bronchopulmonary Dysplasia | 🇪🇺 EU | Order → |
| Ibandronic Acid Hexal ibandronic acid Generic | Hexal AG | Hypercalcemia; Breast Neoplasms; Osteoporosis; Neoplasm Metastasis | 🇪🇺 EU | Order → |
| Ibuprofen/Diphenhydramine Hydrochloride Wyeth Ibuprofen | Wyeth Consumer Healthcare | Pain | 🇪🇺 EU | Order → |
| Idhifa | Celgene Europe BV | Leukemia, Myeloid, Acute | 🇪🇺 EU | Order → |
| Ifinwil eflornithine Orphan | Norgine B.V. | Neuroblastoma | 🇪🇺 EU | Order → |
| Iloperidone Vanda Pharmaceuticals iloperidone | Vanda Pharmaceuticals Netherlands B.V. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2026-02-26 | Order → |
| Imagify perflubutane | Acusphere Ltd | Ultrasonography | 🇪🇺 EU | Order → |
| Imbarkyd bardoxolone methyl Orphan | Reata Ireland Limited | 🇪🇺 EU | Order → | |
| Impulsor milnacipran | Pierre Fabre Medicament | Fibromyalgia | 🇪🇺 EU 2009-11-19 | Order → |
| Infinia alpha-1-antitrypsin Orphan | Kamada BioPharma Limited at Fieldfisher LLP | Genetic Diseases, Inborn; Lung Diseases | 🇪🇺 EU | Order → |
| Inijaq tofacitinib Generic | Gedeon Richter Plc. | Arthritis, Rheumatoid; Colitis, Ulcerative; Arthritis, Juvenile; Arthritis, Psoriatic; Spondylitis, Ankylosing | 🇪🇺 EU 2026-09-17 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.